Volume-Based Procurement in Mainland China: Key Trends and Planning Future Strategies

Volume-Based Procurement in Mainland China: Key trends and planning future strategies Domestically-developed drugs continue to dominate the VBP programs as domestic companies offer high price cuts Number of winning bids Import drugs VBP Round Off-patent brands "4+7" pilot scheme 2 Round 1 Generics 0 Domestic drugs 23 23 6 2 51 Round 2 4 96 Round 3 3 0 188 Round 4 3 2 153 ‣ Clarivate™ With uniform pricing across the nation, both domestic players and multinational companies have now been offered a common platform to participate and sell drugs to public medical institutions. Source: GBI analysis, Clarivate 4

View entire presentation